Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
16.30
-0.07 (-0.46%)
Streaming Delayed Price
Updated: 11:16 AM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 05, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
January 02, 2026
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...
Via
MarketMinute
Topics
Economy
Intellectual Property
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
January 01, 2026
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...
Via
MarketMinute
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
December 23, 2025
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...
Via
MarketMinute
Topics
Intellectual Property
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
December 18, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
December 06, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies
↗
November 21, 2025
The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said.
Via
Stocktwits
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
↗
November 11, 2025
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
Via
Benzinga
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
November 10, 2025
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...
Via
TokenRing AI
Topics
Artificial Intelligence
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
November 07, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....
Via
MarketMinute
Topics
Intellectual Property
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
November 03, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
↗
October 30, 2025
Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairment charges weigh on revenue and profit.
Via
Benzinga
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
October 30, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
October 27, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
October 21, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact
↗
October 14, 2025
Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential success-based milestones.
Via
Benzinga
Topics
Artificial Intelligence
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
↗
October 10, 2025
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.
Via
Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
October 08, 2025
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...
Via
MarketMinute
What's Going On With Nano-Cap Galecto Stock On Tuesday?
↗
October 07, 2025
Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and clinical priorities.
Via
Benzinga
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
September 23, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
5 Best High-Yield Dividend Stocks to Buy Now
↗
September 17, 2025
These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn.
Via
The Motley Fool
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
September 16, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
September 11, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
September 08, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
September 05, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
What's Going On With Takeda Stock On Friday?
↗
August 22, 2025
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.
Via
Benzinga
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
↗
August 21, 2025
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
Via
Benzinga
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
↗
July 30, 2025
Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and rare disease drugs.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.